Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma

Inclusion Criteria

• •Patient must have histologically confirmed B-cell non-Hodgkin lymphoma or classical Hodgkin lymphoma:
• •* Diffuse large B-cell lymphoma (including transformed large cell lymphoma and primary mediastinal B cell lymphoma)
• •* Mantle cell lymphoma
• •* Burkitt's lymphoma
• •* Follicular lymphoma
• •* Small lymphocytic lymphoma
• •* Marginal zone lymphoma
• •* Lymphoplasmacytic lymphoma
• •* Classical Hodgkin lymphoma (including nodular sclerosis, mixed cellularity, lymphocyte rich, and lymphocyte deplete)
• •Patient must have measurable disease, defined as the presence of ≥ 1 lymph node or tumor mass measuring ≥ 1 cm in a single dimension as assessed by CT or MRI.
• •Patient must have had prior treatment with ≥ 2 chemotherapy or chemo-immunotherapy regimens. Prior autologous stem cell transplant is allowed, and prior allogeneic stem cell transplant is allowed as long as the patient has recovered from acute toxicities and is off immunosuppression without evidence of graft versus host disease (GVHD).
• •Patient must be ≥ 18 years of age.
• •Patient must have an ECOG performance status ≤ 2.
• •Patient must have adequate bone marrow reserve at the time of therapy initiation, defined as ANC ≥ 1.0 x 109/L and platelets ≥ 50 x 109/L.
• •Patient must have adequate hepatic function, defined as total bilirubin ≤ 1.5 x ULN and AST/ALT ≤ 3 x ULN.
• •Patient must have adequate renal function, defined as serum creatinine ≤ 2.0 x ULN.
• •Patient must have recovered from any acute toxicities associated with prior therapy to ≤ grade 1.
• •Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
• •Patient (or legally authorized representative, if applicable) must be able to understand and willing to sign an IRB approved written informed consent document.
• •Both men and women and members of all races and ethnic groups are eligible for this trial.